Test drug ASKC202 for advanced lung cancer and MET-positive tumors
Part of Cancer clinical trials.
This Phase 1 trial studies how safe ASKC202 is, what dose is tolerable, and whether it shows early signs of shrinking certain advanced cancers. Depending on your tumor type and prior treatments, ASKC202 may be tested alone or with another drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and agree to follow the study plan
- You are age 18 or older
- You have advanced or metastatic solid tumors, especially unresectable NSCLC (lung cancer)
- For some parts of the study, your tumor must be MET-positive (gene amplification or high protein) and/or have EGFR sensitizing mutations (Ex19del or L858R)
- Your cancer has measurable spots on scans (needed for the dose-expansion part only)
- Your overall health and blood/organ tests are within required limits (and you can usually wait before certain prior medicines)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called KM602 for people with advanced solid tumors that have stopped responding to standard treatments, particularly melanoma and non-small cell lung cancer. It aims to see if the drug is safe and effective in shrinking or controlling tumors.
This trial tests a combination of two experimental drugs (ASKC202 and limertinib) against standard chemotherapy for people with advanced non-small cell lung cancer that has a MET gene change and has stopped responding to earlier targeted therapy (EGFR-TKI). It aims to see if the new combination works better.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
This trial tests a new drug called CKD-703 for people with advanced solid tumors, including a type of lung cancer (non-small cell lung cancer) that has a specific marker called c-Met. The study aims to see if the drug is safe and effective for those who have already tried other treatments that didn't work or caused side effects.
This trial tests a new drug called AK112 for people with a certain type of advanced lung cancer that has specific gene changes (like EGFR or ALK) and where previous targeted therapy pills stopped working. It is a phase 2 study, so it helps find out if the drug is safe and effective, possibly offering a new option when standard treatments fail.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.